All In Biotech

Drug Trial Radar · NCT03248492

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01)

Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 253 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

253

Actual

Start

Aug 25, 2017

Primary completion

Mar 21, 2019

Study completion May 6, 2024

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
AstraZeneca; Daiichi Sankyo Co., Ltd.
First posted
Aug 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

Conditions

  • Breast Cancer

Interventions

  • DS-8201aDrug

    DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)

Locations

99 sites in 9 countries. Site status is shown where the registry gives one.

  • Alaska Urological Institute dba Alaska Clinical Research Center

    Anchorage, Alaska

  • Arizona Oncology Associates

    Tucson, Arizona

  • The Regents of the University of California

    Los Angeles, California

  • Sharp Clinical Oncology Research

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • Sansum Clinic

    Santa Barbara, California

  • Innovative Clinical Research Institute, LLC

    Whittier, California

  • Sylvester Comprehensive Cancer Center - Deerfield Beach

    Boca Raton, Florida

  • Specialist Global Research

    Hialeah, Florida

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida

  • Piedmont Cancer Institute

    Atlanta, Georgia

  • Straub Medical Center

    Honolulu, Hawaii

  • University of Hawaii

    Honolulu, Hawaii

  • Norton Healthcare

    Louisville, Kentucky

  • University of Louisville Research Foundation

    Louisville, Kentucky

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists

    East Setauket, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Aultman Hospital Cancer Center

    Canton, Ohio

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • UPMC Cancer Center

    Pittsburgh, Pennsylvania

  • St Francis Hospital

    Greenville, South Carolina

  • Accurate Clinical Research

    Baytown, Texas

  • Texas Oncology, P.A.

    Dallas, Texas

  • Texas Oncology - Memorial City

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • The Methodist Hospital Research Institute

    Houston, Texas

  • Texas Oncology, P.A. - Longview

    Tyler, Texas

  • The University of Texas Health Science Center at Tyler

    Tyler, Texas

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Providence Regional Medical Center - Everett

    Everett, Washington

  • Imeldaziekenhuis

    Bonheiden, Belgium

  • Grand Hôpital de Charleroi

    Charleroi, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHU Sart Tilman

    Liège, Belgium

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.